Pfizer struck a partnership with Starna Therapeutics to expand its immunology pipeline into preclinical in vivo CAR-T programs. Under the deal, Pfizer gains global rights outside Greater China to three in vivo CAR-T therapies targeting undisclosed autoimmune indications and also receives rights to use Starna’s technology across inflammation, immunology, and oncology. The financial terms include a $330 million upfront payment and up to $2.3 billion in additional milestones, with Starna eligible for royalties on sales of any approved products. Pfizer said it will manufacture the therapies for clinical trials in the United States. The transaction reinforces a growing industry push toward in vivo approaches that could shorten or simplify CAR-T manufacturing compared with ex vivo workflows. For biotech stakeholders, the deal signals where platform investment momentum is concentrating as more companies pursue engineered cellular modalities without full-scale manufacturing burdens.